Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Thrombosis And Hemostasis Biomarkers Market Grown from 2024 to 2025?

Recently, the thrombosis and hemostasis biomarkers market has witnessed significant expansion. This market is set to escalate from $4.8 billion in 2024 to $5.17 billion in 2025, marking a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include an upsurge in cardiovascular diseases, the advancing age of the worldwide population, a rise in cancer-associated thrombosis, an increase in obesity and inactive lifestyles, as well as a surge in instances of diabetes and metabolic syndrome.

What Growth Rate Is Anticipated for the Thrombosis And Hemostasis Biomarkers Market in the Coming Years?

Expectations are high for a significant expansion in the thrombosis and hemostasis biomarkers market in the upcoming years. The market is projected to mature to a whopping $6.87 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period is linked to the rising prevalence of stroke and ischemic conditions, heightened awareness of venous thromboembolism, increased cases of hemophilia and other bleeding disorders, expanding number of surgeries, and growing healthcare spending. Key trends to watch out for in the forecast period include breakthroughs in biomarker detection methodology, creation of highly-sensitive assays for D-dimer and fibrinogen, the rise of point-of-care diagnostic tools, the application of AI in biomarker analysis and forecasting, and automation in laboratory diagnostic processes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24724&type=smp

Who Are the Leading Companies in the Thrombosis And Hemostasis Biomarkers Market?

Major companies operating in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson and Company (BD), Mayo Clinic Laboratories, bioMérieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., Cincinnati Children’s Hospital Medical Center, ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH

What Are the Key Drivers of the Thrombosis And Hemostasis Biomarkers Market?

The thrombosis and hemostasis biomarkers market is predicted to expand due to the increasing need for precise and targeted treatments. These advanced treatments are designed to mitigate the specific genetic and molecular attributes of a patient’s disease, improving efficiency and reducing harmful effects. The understanding and recognition of genetic and molecular disparities in diseases are rising, leading to a surge in demand for treatments specifically tailored to individual patients. This not only enhances the effectiveness but also lowers side effects. The emerging requirement for accurate and targeted treatments contributes to the growth of thrombosis and hemostasis biomarkers by facilitating the creation of precise diagnostic tools. These tools can recognize specific biomarkers, leading to more targeted treatments for clotting disorders and an overall improvement in patient outcomes. For example, in March 2024, Novotech, a contract research organization from Australia, reported that, out of 217 FDA-approved oncology therapies by the end of 2023, 43% are identified as precision oncology treatments. Out of these, 78 incorporate Deoxyribonucleic Acid (DNA) or Next-generation sequencing (NGS)-detectable biomarkers. As such, the thrombosis and hemostasis biomarkers market is likely to thrive due to the rising demand for accurate and specific treatments.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24724&type=smp

What Are the Key Market Segments in the Thrombosis And Hemostasis Biomarkers Industry?

The thrombosis and hemostasis biomarkers market covered in this report is segmented –

1) By Product: Reagents And Consumables, Analyzers

2) By Test Type: D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin, Factor VIII, Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, Other Test Types

3) By Application: Cardiovascular Disorders, Neurological Disorders, Oncology, Pregnancy-Related Disorders, Orthopedic Procedures

4) By End User: Hospitals, Diagnostics Laboratories, Pharmaceutical Companies, Academic Institutions, Home Healthcare Settings

Subsegments:

1) By Reagents And Consumables: Coagulation Reagents, Control And Calibration Materials, Immunoassay Kits

2) By Analyzers: Fully Automated Coagulation Analyzers, Semi-Automated Coagulation Analyzers, Point-Of-Care Coagulation Devices

What Are the Latest Trends in the Thrombosis And Hemostasis Biomarkers Market?

Major firms engaged in the thrombosis and hemostasis biomarkers market are prioritizing the development of innovative solutions, such as automated VWF activity assays, to upgrade the precision and consistency in diagnosing bleeding disorders. An automated VWF activity assay is a sophisticated lab test which uses techniques like immunoturbidimetry or chemiluminescence to gauge the efficacy of the von Willebrand factor. This is a blood glycoprotein involved in hemostasis that is critical for platelet attachment and factor VIII stabilization, and it aids in diagnosing and tracking Von Willebrand disease by binding to the platelet glycoprotein Ib. For example, Siemens Healthineers, a medical technology firm based in Germany, introduced the INNOVANCE VWF Ac assay in October 2022. It is a fully automated VWF activity assay engineered to optimize the measurement of von Willebrand factor (VWF) activity. This assay employs VWF:GPIbM technology, which directly inspects platelet binding activity, providing superior accuracy and sensitivity compared to older methods. VWF is a globally acknowledged biomarker associated with both bleeding and thrombosis, its presence and activity help predict the probability of bleeding episodes and clot formation. It allows for the identification of previously hard to detect VWF variants, promoting improved diagnosis and treatment of von Willebrand disease (VWD). Moreover, the assay syncs with the latest guidelines from the American Society of Hematology (ASH), International Society on Thrombosis and Hemostasis (ISTH), and the National Hemophilia Foundation (NHF), underscoring its clinical significance and advance in diagnostic methodology.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/thrombosis-and-hemostasis-biomarkers-global-market-report

What Are the Key Regional Markets in the Thrombosis And Hemostasis Biomarkers Industry?

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thrombosis and hemostasis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24724

This Report Delivers Insight On:

1. How big is the thrombosis and hemostasis biomarkers market, and how is it changing globally?

2. Who are the major companies in the thrombosis and hemostasis biomarkers market, and how are they performing?

3. What are the key opportunities and risks in the thrombosis and hemostasis biomarkers market right now?

4. Which products or customer segments are growing the most in the thrombosis and hemostasis biomarkers market?

5. What factors are helping or slowing down the growth of the thrombosis and hemostasis biomarkers market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model